» Articles » PMID: 19253061

Epithelial Ovarian Cancer: Does the Time Interval Between Primary Surgery and Postoperative Chemotherapy Have Any Prognostic Importance?

Overview
Publisher Wiley
Date 2009 Mar 3
PMID 19253061
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Worldwide, much effort is used every day to perform optimal surgery in the treatment of epithelial ovarian cancer. Treatment of ovarian cancer is a combination of surgery with optimal debulking followed by chemotherapy. However, the optimal timing of postoperative chemotherapy for ovarian cancer remains poorly defined. The literature is made up of seven studies performed in different ways and which have included varying prognostic factors. The general supposition is that the time interval (TI) does not have a prognostic influence but experimental studies have shown that it does affect the prognosis of the cancer. This commentary focuses on the importance of the TI between surgery and postoperative chemotherapy in this horrible disease.

Citing Articles

The impact of interval between primary cytoreductive surgery with bowel resection and initiation of adjuvant chemotherapy on survival of women with advanced ovarian cancer: a multicenter cohort study.

Lee Y, Kim S, Kollara A, Brown T, May T J Gynecol Oncol. 2022; 33(6):e76.

PMID: 36047378 PMC: 9634098. DOI: 10.3802/jgo.2022.33.e76.


Survival and prognostic factors in women treated for epithelial ovarian cancer in western region of Saudi Arabia.

Sait K, Alam M, Haque A, Sait H, Sait M, Anfinan N Saudi Med J. 2022; 43(2):146-155.

PMID: 35110339 PMC: 9127918. DOI: 10.15537/smj.2022.43.2.20210626.


A mouse model of neoadjuvant chemotherapy followed by interval cytoreductive surgery indicates impaired efficacy of perioperative cisplatin.

Clark M, Kollara A, Brown T, May T J Ovarian Res. 2021; 14(1):157.

PMID: 34784944 PMC: 8594094. DOI: 10.1186/s13048-021-00895-w.


Clinical factors associated with prognosis in low-grade serous ovarian carcinoma: experiences at two large academic institutions in Korea and Taiwan.

Kang J, Lai Y, Cheng W, Kim H, Kuo K, Chen Y Sci Rep. 2020; 10(1):20012.

PMID: 33203969 PMC: 7672053. DOI: 10.1038/s41598-020-77075-1.


Interval between secondary cytoreductive surgery and adjuvant chemotherapy is not associated with survivals in patients with recurrent ovarian cancer.

Jeong S, Choi C, Kim T, Lee J, Kim B, Bae D J Ovarian Res. 2020; 13(1):1.

PMID: 31892329 PMC: 6937657. DOI: 10.1186/s13048-019-0602-5.